Xingping Su
University of Oxford
6 Papers
Xingping Su is an academic researcher from University of Oxford. The author has contributed to research in topics: Chemistry & Idiopathic pulmonary fibrosis. The author has an hindex of 2, co-authored 6 publications. Previous affiliations of Xingping Su include Sichuan University.
Chat about Author
Papers
Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2
Zhihao Liu,Xi Hu,Qi-Wei Wang,Xiuli Wu,Qiangsheng Zhang,Wei Wei,Xingping Su,Hualong He,Shu-Yan Zhou,Rong Hu,Tinghong Ye,Yongxia Zhu,Ning-Yu Wang,Luoting Yu +13 more
TL;DR: Zhang et al. as discussed by the authors reported a series of EZH2-targeted proteolysis targeting chimeras (PROTACs) that induce proteasomal degradation of PRC2 components.
93
Repurposing of the anti-helminthic drug niclosamide to treat melanoma and pulmonary metastasis via the STAT3 signaling pathway
Yongxia Zhu,Weiqiong Zuo,Lijuan Chen,Shasha Bian,Jiayu Jing,Cailin Gan,Xiuli Wu,Hongyao Liu,Xingping Su,Wanglai Hu,Yuqi Guo,Wang Yue,Tinghong Ye +12 more
TL;DR: Niclosamide significantly inhibited pulmonary metastasis in a B16-F10 melanoma lung metastasis model, including the number of lung metastatic nodules and lung/body coefficient and a marked reduction in myeloid-derived suppressor cells (Gr1+CD11b+) infiltration in the pulmonary metastatic tissue was observed.
37
A novel multikinase inhibitor SKLB-YTH-60 ameliorates inflammation and fibrosis in bleomycin-induced lung fibrosis mouse models.
Hongyao Liu,Xiuli Wu,Cailing Gan,Liqun Wang,Guan Wang,Lin Yue,Zhihao Liu,Wei Wei,Xingping Su,Qianyu Zhang,Zui Tan,Yuqin Yao,Liang Ouyang,Luoting Yu,Tinghong Ye +14 more
TL;DR: YTH-60 as discussed by the authors has shown an acceptable oral bioavailability (F = 17.86%) and appropriate eliminated half-life time (T1/2 = 8.03 hours).
18
Matrix metalloproteinases inhibitors in idiopathic pulmonary fibrosis: Medicinal chemistry perspectives.
TL;DR: In this paper, the authors present the latest developments in MMP inhibitors, including pharmacophores, binding modes, selectivity and optimization strategies, and discuss the future development direction of MMP inhibitor based on emerging tools and techniques.
14
Design, synthesis and biological evaluation of 1H-pyrrolo[2,3-b]pyridine derivatives as potent fibroblast growth factor receptor inhibitors
TL;DR: A series of 1H-pyrrolo[2,3-b]pyridine derivatives with potent activities against FGFR1, 2, and 3 exhibited potent FGFR inhibitory activity in vitro, and compound 4h with low molecular weight would be an appealing lead compound which was beneficial to the subsequent optimization.